APA

Hyman D. M., Sill M. W., Lankes H. A., Piekarz R., Shahin M. S., Ridgway M. R., Backes F., Tenney M. E., Mathews C. A., Hoffman J. S., Aghajanian C. & Hensley M. L. (20170530). A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D. : Gynecologic oncology.

Chicago

Hyman David M, Sill Michael W, Lankes Heather A, Piekarz Richard, Shahin Mark S, Ridgway Mildred R, Backes Floor, Tenney Meaghen E, Mathews Cara A, Hoffman James S, Aghajanian Carol and Hensley Martee L. 20170530. A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D. : Gynecologic oncology.

Harvard

Hyman D. M., Sill M. W., Lankes H. A., Piekarz R., Shahin M. S., Ridgway M. R., Backes F., Tenney M. E., Mathews C. A., Hoffman J. S., Aghajanian C. and Hensley M. L. (20170530). A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D. : Gynecologic oncology.

MLA

Hyman David M, Sill Michael W, Lankes Heather A, Piekarz Richard, Shahin Mark S, Ridgway Mildred R, Backes Floor, Tenney Meaghen E, Mathews Cara A, Hoffman James S, Aghajanian Carol and Hensley Martee L. A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D. : Gynecologic oncology. 20170530.